BAIT

PDGFRA

CD140A, PDGFR-2, PDGFR2, RHEPDGFRA
platelet-derived growth factor receptor, alpha polypeptide
GO Process (35)
GO Function (8)
GO Component (6)

Gene Ontology Biological Process

Homo sapiens

Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

Publication

A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.

Xu F, Tong M, Tong CSW, Chan BKC, Chu HY, Wong TL, Fong JHC, Cheung MSH, Mak KH, Pardeshi L, Huang Y, Wong KH, Choi GCG, Ma S, Wong ASL

Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinations, we designed a combinatorial CRISPR-Cas9 screen to inhibit druggable targets. Coblockade of the N-methyl-d-aspartate receptor (NMDAR) with targets of first-line kinase inhibitors reduced hepatocellular carcinoma (HCC) ... [more]

Cancer Res Dec. 15, 2020; 81(24);6219-6232 [Pubmed: 34666996]

Throughput

  • Low Throughput

Ontology Terms

  • phenotype: growth abnormality (HP:0001507) [viability (PATO:0000169)]

Additional Notes

  • CRISPR GI screen
  • Cell Line: MHCC97L HCC
  • Experimental Setup: Timecourse
  • GIST: A-phenotypic negative genetic interaction
  • Library: Targeted CRISPRn library
  • Significance Threshold: mean log2 ratios of <-0.51 at P<0.05

Curated By

  • BioGRID